TRASTUZUMAB TRASTUZUMAB 5 2 livertox summary trastuzumab is a humanized monoclonal antibody to the human epidermal growth factor receptor 2 (HER2) which is used in combination with
TRASTUZUMAB āļĒāļē trastuzumab (āļāļĢāļēāļŠ āļāļđ āļāļđ āđāļĄāļ) āļŦāļĢāļ·āļāļāļ·āđāļāļāļēāļĢāļāđāļē herceptin (āđāļŪāļāļĢāđ āđāļāļ āļāļīāļ) āđāļāđāļāļāļēāļĢāļĢāļąāļāļĐāļēāđāļāļāļĄāļļāđāļāđāļāđāļē (targeted therapy) āļāļāļāļĪāļāļāļīāđāļāļģāđāļāļēāļ°āđāļāļēāļ°āļāļāļāđāļāđāļāļĨāļĨāđāļĄāļ°āđāļĢāđāļ āļāļēāļāđāļāļīāļ trastuzumab āđāļāļĢāđāļĄāļāļąāđāļāļŠāļĨāđāļāļ redness irritation at the injection site, diarrhea, muscle joint back pain, stomach abdominal pain, headache, trouble sleeping, nausea, vomiting, mouth sores, āđāļāļāļąāļŠāļŠāļđāļāļŠāļļāļ trastuzumab āļŠāļāļīāļāļāļĢāļĩ
TRASTUZUMAB trastuzumab side effects · heart problems; · nausea, diarrhea, weight loss; · headache; · trouble sleeping, feeling tired; · low blood cell ufabet trastuzumab āđāļ§āđāļāļāļēāļŠāļīāđāļāļāļĩāđāļāļĩāļāļĩāđāļŠāļļāļ tamura k, tsurutani j, takahashi s, et al trastuzumab deruxtecan (ds 8201a) in patients with advanced her2 positive breast cancer previously treated with āļŠāļĨāđāļāļāđāļ§āđāļāļāļĢāļ trastuzumab āđāļĨāđāļāļāđāļēāļāļĄāļ·āļāļāļ·āļ